MBX Biosciences doses first patient in Phase 3 oPTimize trial
MBX Biosciences has dosed the first patient in its Phase 3 oPTimize trial of once-weekly canvuparatide.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.